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Abstract
Objective: With increasing age, the prevalence of aortic stenosis grows exponentially, increasing left heart pressures and
potentially leading to myocardial hypertrophy, myocardial fibrosis and adverse outcomes. To identify patients who are at
greatest risk, an outpatient model for risk stratification would be of value to better direct patient imaging, frequency of
monitoring and expeditious management of aortic stenosis with possible earlier surgical intervention. In this study, a relatively
simple model is proposed to identify myocardial fibrosis in patients with a diagnosis of moderate or severe aortic stenosis.
Design: Patients with moderate to severe aortic stenosis were enrolled into the study; patient characteristics, blood
work, medications as well as transthoracic echocardiography and cardiovascular magnetic resonance were used to
determine potential identifiers of myocardial fibrosis.
Setting: The Royal Brompton Hospital, London, UK
Participants: One hundred and thirteen patients in derivation cohort and 26 patients in validation cohort.
Main outcome measures: Identification of myocardial fibrosis.
Results: Three blood biomarkers (serum platelets, serum urea, N-terminal pro-B-type natriuretic peptide) and left
ventricular ejection fraction were shown to be capable of identifying myocardial fibrosis. The model was validated in a
separate cohort of 26 patients.
Conclusions: Although further external validation of the model is necessary prior to its use in clinical practice, the
proposed clinical model may direct patient care with respect to earlier magnetic resonance imagining, frequency of moni-
toring and may help in risk stratification for surgical intervention for myocardial fibrosis in patients with aortic stenosis.
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Introduction
Aortic stenosis is a common valvular pathology with a
prevalence that increases exponentially with age.1 The
increased ventricular pressures associated with aortic ste-
nosis lead to myocardial hypertrophy which over time
may lead to myocardial fibrosis (MF) and heart failure.2
Myocardial fibrosis identified on histopathology
gives good correlation with measurements on late gad-
olinium enhancement (LGE) cardiovascular magnetic
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resonance (CMR).3 LGE measured on CMR is a pre-
dictor of heart failure and cardiovascular complica-
tions requiring hospitalizations and has been used to
detect replacement MF.4,5 Furthermore, left ventricu-
lar MF is associated with left atrial functional abnor-
malities,6 advanced cardiac hypertrophy,5 and
importantly both its presence and total burden are
independent predictors of mortality in aortic stenosis,
confirming the utility of CMR for risk stratification.7–9
The only current treatment for aortic stenosis is aortic
valve replacement (AVR). While AVR may lead to
regression of myocardial hypertrophy, it does not lead
to regression of focal fibrosis as measured by LGE,10 but
can halt progression. Detection of early fibrosis by LGE
is therefore important to improve clinical outcomes and
possibly help identify patients that need earlier treatment
to limit progression of fibrosis and limit the mortality
risk associated with it.5,10 Nevertheless, due to limited
resources and the variable accessibility to CMR, it is
important to risk stratify patients for CMR given that
scanning all patients with AS would not be feasible.
Predictors of MF have been previously investigated.
However, markers such as lipoprotein(a),11 serum sST2
(member of interleukin-1 receptor)12 have not been
found to be suitable for the prediction of MF.11,12
Electrocardiographic findings of lower voltage
transmission13 as well as fragmented QRS complexes14
among patients with hypertrophic cardiomyopathy
may identify MF; however, the myocardial tissue has
to be sufficiently fibrosed for derangement of electrical
conduction to be identified.
On the other hand, plasma levels of miRNA-21 were
previously shown to be associated with MF.15,16 In
addition, the cardiac myosin-binding protein C, a
marker for myocardial injury and fibrosis, was found
to correlate with hypertrophy and fibrosis as measured
by LGE and may provide future direction for investi-
gation.17 Early detection of fibrosis based on other
blood tests may be of utility to identify patients with
AS at higher risk of MF, warranting further multimo-
dality imaging and possible intervention.18
The purpose of this investigation was to develop a
clinical risk score that would allow for the identifica-
tion of patients at risk of having any myocardial
replacement fibrosis, defined as either non-infarct mid-
wall fibrosis or subendocardial-infarction pattern fibro-
sis, as both of these are associated with worse prognosis
in patients with aortic stenosis. The objective of the
“Fibrosis Risk Score” is to risk stratify patients for
further imaging and direct management.
Methods
The study has been approved by the National Ethics
Committee and the Institutional Review Board of
Royal Brompton Hospital, London, UK and under-
taken in accordance with the ethical standards detailed
in the Declaration of Helsinki. Written consent was
obtained from all patients. This work represents a
sub-study of prospectively recruited patients in the
CMR study (ClinicalTrials.gov Identifier:
NCT00930735).
At the Royal Brompton Hospital, CMR is routinely
recommended for all patients with significant AS (in
practice moderate/severe) and where the clinical team
requires further information regarding the severity of
AS, left ventricular (LV) function or aortic dimensions,
thus enabling recruitment of patients with CMR scans
for the study.
The derivation cohort consisted of 113 consecutive
patients with AS who underwent CMR between 2011
and 2014 and had LGE. Additionally, 26 further
patients were recruited in 2015 and formed the valida-
tion cohort.
Patients with disseminated malignancy, severe aortic
regurgitation, moderate or severe mitral regurgitation/
stenosis, previous valve replacement operations, con-
traindications to CMR (including pacemaker and
defibrillator implantation), and an estimated
glomerular filtration rate (Cockcroft-Gault equation)
of <30ml/min were excluded.
Data collection
Patient demographic characteristics and medical histo-
ries were collected from the patient and their hospital
or community records and reviewed on the day of the
CMR. Medical conditions and prescribed medications
were recorded. The presence of coronary artery disease
was defined as prior coronary revascularization or the
presence of significant coronary artery stenosis: >50%
lumen diameter narrowing of a vessel of 2mm diameter
or greater as assessed by invasive or computed tomog-
raphy coronary angiography.
Cardiovascular magnetic resonance
CMR was performed using a 1.5 T scanner (Sonata or
Avanto, Siemens, Erlangen, Germany) and a standar-
dised protocol as described previously.11
In brief, balanced steady state free precession
(SSFP) at end-expiration was used to guide acquisition
of a vertical long axis (VLA) cine for initial localizer
images. From these, two, three and four chamber views
cines were undertaken. Contiguous 10mm short axis
slices of the LV were then taken from base to apex.
Following administration of gadolinium contrast
agent (Gadovist, Schering AG, Berlin, Germany),
inversion recovery-prepared spoiled gradient echo
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images were acquired in standard long- and short-axis
views to detect areas of LGE.
Image analysis
Once all imagining data have been collected, for both
the derivation and validation cohorts, image analysis
was undertaken using a dedicated software
(CMRtools, Cardiovascular Imaging Solutions,
London, UK). The presence and pattern of LGE
were assessed on anonymised images by two indepen-
dent blinded expert observers (Level 3 Society for
Cardiovascular Magnetic Resonance accreditation)
and used to categorise each patient according to the
presence or absence of myocardial fibrosis, and if pre-
sent, whether it was midwall fibrosis or subendocardial-
infarction pattern fibrosis. The primary analysis was
based on the presence of any fibrosis (non-infarction
midwall or subendocardial-infarction pattern).
Reproducibility of CMR imagining parameters has
been previously established at Royal Brompton
Hospital.19
In addition, echo parameters including peak veloci-
ty, peak and mean gradients and derived aortic valve
area parameters were recorded and used as possible
variables in identifying myocardial fibrosis.
Biomarker analysis
During the 2011–2014 (derivation cohort) and 2015
(validation cohort) time periods, blood samples were
collected on the same day as the CMR and stored.
Biomarker analysis was undertaken in the accredited
biochemistry laboratory at Royal Brompton Hospital
upon completion of the recruitment to both studies.
Given that the lab defined urea as abnormal at val-
ues 7.5mmol/L, and NT-Pro BNP defined at lev-
els 450 pg/mL; these variables were reported in a
dichotomous manner for statistical analysis. The bio-
marker data for the derivation and validation cohorts
were statistically analysed at the same time.
Statistical analysis
For baseline patient characteristics, continuous varia-
bles are presented as mean standard deviation (SD),
and categorical variables are presented as absolute
numbers and percentages. Mann–Whitney-Wilcoxon
test were used for continuous variables and Fisher
exact test for categorical variables for baseline charac-
teristics among fibrosis and no fibrosis patient groups.
Analysis was performed using Stata 15.1 (College
Station, Texas, USA).
All variables were first included in univariable logis-
tic regression models and these were used to assess the
best functional form for continuous variables (linear
scale, log scale, or binary cut-off). Univariate and mul-
tivariable Cox models were generated, and forward
stepwise selection was used to find the optimal logistic
regression model to predict fibrosis from all of the
potential predictors. This multivariable model was
used to assign predicted probabilities of fibrosis to
each patient and verified using the Hosmer–
Lemeshow goodness-of-fit test and the receiver opera-
tor curve (ROC) statistic. The model was firstly inter-
nally validated using a bootstrap method. Secondly,
the model was used to predict the presence of any fibro-
sis for each patient in the validation cohort and
assessed how the prediction related to the CMR scan
findings.
Results
All the patients who provided their consent and met the
inclusion criteria were included in the study, there were
no further exclusions. Overall, 113 patients with mod-
erate or severe AS (mean age 76 10; 69% male)
underwent CMR imaging to determine the presence
of midwall fibrosis or infarction as shown in
Supplemental Figure 1. Baseline patient characteristics
and variables investigated are shown in Supplemental
Table 1 and Supplemental Text.
Thirty-seven patients (32.7%) showed no evidence
of fibrosis. Seventy-six (67.3%) patients had fibrosis,
40 of which had midwall fibrosis and 36 had
subendocardial-infarction pattern fibrosis. Eighty-five
variables based on patient demographics, biomarker
results, echocardiography and CMR parameters were
assessed (variables with p< 0.2 included in Table 1).
Variables with p 0.2 on the univariable analysis
results were subsequently used in the multivariable
logistic regression models with forward stepwise selec-
tion for the computation of the most favourable logis-
tic regression model in identifying fibrosis.
In a multivariable model, platelet count, urea,
LVEF and NT-Pro BNP remained the only significant
variables (p< 0.05) (Table 2).
The final multivariable model, based on logistic
regression model, was used to estimate the predicted
probability of fibrosis to each patient. This was based
on the three biomarkers and the LVEF as follows:
Probability of Fibrosis
¼ expit 911:31 0:84P10  4:03U  0:94L  3:75N
 
where P is the number of platelets, U is 1 if
Urea 7.5mmol/L and 0 otherwise, L is the percentage
LVEF, N is 1 if NT-ProbBNP 450 pg/mL and 0 oth-
erwise, and expit is the function where expit xð Þ ¼ x1þx.
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A histogram of these probabilities is shown in
Figure 1.
Depending on the clinical setting, the model allows
for variable cut-off values to adjust sensitivity and spe-
cificity according to clinical requirements. For example,
a probability cut-off of 0.50 will give 90% sensitivity of
identifying fibrosis with 55% specificity, whereas a cut-
off value of 0.90 will give 50% sensitivity with a spe-
cificity of 93%.
Internal validation
A Hosmer–Lemeshow goodness-of-fit test indicated
acceptable calibration of the model (p¼ 0.44). The
AUC from the receiver operating characteristic
(ROC) was 0.86, suggesting good discrimination.
A bootstrap method was used to internally
validate the discrimination of the model and the bias
was estimated to be 3.9% (95% confidence interval
(CI) 0.2%–9.9%) suggesting only a small amount
of bias.
External validation
In the validation cohort, the percentage risk of fibrosis
divided into four groups, (Table 3) correlated well with
the true presence or absence of fibrosis based on CMR
(area under ROC curve 0.73). However, in view of the
small number of patients, the confidence interval was
relatively large (95% CI 0.50–0.97). Nonetheless, this
Table 2. Multivariable identifiers of fibrosis.
Variable Odds ratio 95% confidence interval p value
Platelets (per 10) 0.84 0.75 0.94 0.002
Urea (7.5 mmol/L) 4.03 1.24 13.15 0.021
LV EF (per %) 0.94 0.89 0.99 0.023
NT Pro BNP (450 pg/mL) 3.75 1.06 13.34 0.041
Note: In a multivariable model, platelets, urea, LVEF and NT-Pro BNP were associated with midwall and subendocardial-infarction pattern type fibrosis.
Table 1. Univariate identifiers of fibrosis.
Variable Odds ratio 95% confidence interval p value
NT-Pro BNP (450 pg/mL) 7.15 2.81 18.20 <0.001
BNP (per log pg/mL) 2.16 1.32 3.55 <0.001
LV EF (per 1%) 0.95 0.92 0.98 0.002
Platelets (per 10) 0.89 0.82 0.97 0.007
Age (per 10 years) 1.64 1.10 2.43 0.015
LV ESV (per 10) 1.12 1.02 1.23 0.016
Urea (7.5 mmol/L) 3.15 1.24 8.00 0.016
Euroscore II (per 1) 1.28 1.04 1.57 0.018
LA Volume (per 100 mm) 3.03 1.21 7.58 0.018
OPG (per log pmol/L) 3.20 1.17 8.80 0.024
Bilirubin (per lmol/L) 1.11 1.01 1.22 0.028
LA vol indexed (per 100 mL) 6.09 1.16 31.88 0.033
LA area 4Ch (per 100 mm) 1.06 1.00 1.12 0.034
BMI (per kg/m2) 0.92 0.84 1.00 0.053
OPN (per log ng/mL) 2.81 0.99 7.98 0.053
Albumin (per g/L) 0.89 0.79 1.00 0.055
LV EDV (per 10) 1.07 1.00 1.15 0.057
Creatinine (per 10 lmol/L) 1.16 0.99 1.35 0.062
Sodium (per mmol/L) 0.89 0.78 1.01 0.069
LV mass (per 10 g/m2) 1.08 0.99 1.17 0.081
LA area 2Ch (per 100 mm) 1.04 0.99 1.10 0.083
Troponin I (per log mg/L) 2.21 0.88 5.57 0.092
Wall thickness (per mm) 1.13 0.96 1.34 0.14
Echo PG (per 10) 0.90 0.79 1.04 0.15
Echo MG (per 10) 0.86 0.70 1.07 0.17
Note: The table shows the variables associated with the presence of any fibrosis. Variables with p 0.2 on the univariable analysis results, which were
subsequently used in the derivation of the model, are reported from the total of 85 variables used.
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process supported the findings of the internal
validation.
Discussion
Using a large cohort of patients with AS who had
undergone CMR to determine myocardial fibrosis,
our team has developed and validated a risk score for
fibrosis based on simple imaging and biomarker
parameters.
Of the final variables that were computed into the
Risk of Fibrosis Equation, some have been previously
implicated in cardiovascular pathologies. NT pro-
BNP, for example, has been previously reported to be
a strong predictor of cardiovascular mortality20 and
was identified as the most important variable in pre-
dicting cardiovascular death in patients with stable cor-
onary heart disease.21 In AS patients, the biomarker
was linked to disease severity and was proposed to be
of use for post-surgical follow-up.22,23 It should be
noted, however, that aside from the myocardial
fibrosis, a number of additional pre-disposing factors
as well as confounders may be further correlated with
biomarker expression, such as pressure overload, dis-
ease severity, cardiomyocyte hypertrophy, among
others.24,25
Current guidelines recommend intervention to
relieve aortic stenosis in the presence of symptoms or
LVEF <50%.26,27 However, these guidelines are poten-
tially limited because they allow patients to decompen-
sate before they are eligible for intervention;
subsequently, patients may have a poorer response to
treatment. Therefore, appropriate use of CMR to iden-
tify earlier signs of decompensation, including fibrosis,
might enable better monitoring and appropriate inter-
vention for such patients.28 CMR represents an excel-
lent imaging modality for such patients as it is safe and
radiation-free and also gives information on the valve
(gradient, anatomy, valve area), the aorta (size, coarc-
tation) and the myocardium (LV and RV function, left
atrial (LA) size, myocardial thickness and fibrosis).
However, not all patients can undergo CMR and, cru-
cially, its use is limited by clinical availability in many
parts of the country and indeed the world. Therefore, a
simple risk score to identify fibrosis is an important
step as it has two potential uses.
The score can be used to streamline the use of CMR
with LGE in patients with AS. The flexibility and ver-
satility of the model allow it to be modified to support
different clinical environments and needs. For example,
where CMR is easy to obtain, a low cut-off value of
fibrosis risk (e.g. 20%) could be used to allow increased
sensitivity (95% in this case), whereas when CMR is
difficult to access, a high cut-off (e.g. 90%) will allow
high specificity (93%). Furthermore, even if the
patients do undergo CMR, if the need for gadolinium
is negated (by correctly estimating the presence/absence
of fibrosis in advance), then the duration of the scan
could be quicker and not require intravenous cannula-
tion or contrast administration, which can reduce both
the time of the scan and the cost.
This model has the potential to be used as a serial
early marker of decompensation, allowing annual mon-
itoring of patients with asymptomatic AS. Once the
percentage risk increases, it would be suggestive of
decompensation and CMR can be arranged and the
patient potentially considered for surgery. However,
this will need to be fully validated in a prospective
study.
Study limitations
Although the model is designed to “identify” the pres-
ence of myocardial fibrosis, we cannot comment on the
potential impact on management and subsequent inter-
vention and whether this can improve outcomes.
Table 3. Fibrosis risk prediction. How the fibrosis risk pre-
dicted was associated with the true presence or absence of
fibrosis.
Predicted risk %
Total number
of patients
Patients with
fibrosis (%)
0–25 2 0 (0)
25–50 1 1 (100)
50–75 6 4 (67)
75–100 17 15 (88)
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Figure 1. Histogram of the probability of fibrosis. The model is
based on the platelet count, urea level, NT-Pro BNP level and left
ventricular ejection fraction (LVEF), from which the probability of
any fibrosis can be calculated for each patient. The sensitivity is
shown in green and the specificity in golden-brown. The red bar
represents patients who had fibrosis on CMR, and the blue bar
represents patients who did not have fibrosis.
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Although it would be logical to assume this given the
evidence of worse outcome in the patients with fibro-
sis,8,28 this needs to be confirmed either in a prospective
study or retrospectively in multi-centre work where
both CMR and biomarker parameters are available
from the time of the CMR. The midwall and infarction
fibrosis groups were merged in order to provide ade-
quate power; however, a separate model for each of
these pathologies might have better sensitivity and spe-
cificity. Nonetheless, both midwall and infarction fibro-
sis have similarly adverse prognosis justifying using a
combined approach.9 LGE has been utilized in the past
for the assessment of mid-wall fibrosis and subendocar-
dial delayed enhancement.29 Our study focused on
LGE imagining to identify myocardial fibrosis in a
dichotomous (present/absent) manner. In the future,
assessing the validity of the model to identify graded
severity of myocardial fibrosis as identified by LGE or
utility of other imagining modalities such as T1 map-
ping may be of benefit. In addition, although our
model has shown strong internal validation and good
external association from a separate small cohort in
our institution, we did not have large external valida-
tion from a separate institution which is the gold stan-
dard for any risk model. Furthermore, this work was
carried out in a single institution with a predominantly
Caucasian patient population, therefore it remains to
be seen if it would be applicable in other populations.
Also, the potential effect of medication use on the final
four variables within the fibrosis identification model
has not been evaluated in our study and may have
played an effect on the results, although such an
effect would have weakened the associations seen. As
such we believe that the medication use did not influ-
ence the conclusion of our paper. Finally, our troponin
assays have a lower limit of detection as 18 ng/L,
whereas more modern assays have thresholds as low
as 1.2 ng/L,30 therefore potentially reducing its effect.
Conclusions
We have developed, internally validated and externally
confirmed a flexible fibrosis risk model in aortic steno-
sis which could be used in clinical practice to reduce the
need for CMR, but also for serial monitoring and iden-
tifying patients at risk of early decompensation. The
model is versatile and can be adjusted according to
the clinical need. Prior to full implementation in clinical
practice, however, a full external validation and inves-
tigation into the association of this model with longer-
term clinical outcomes is required.
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